tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Thiogenesis Therapeutics Advances in Mitochondrial Disease Trials

Story Highlights
Thiogenesis Therapeutics Advances in Mitochondrial Disease Trials

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Thiogenesis Therapeutics Corp. has announced progress in its clinical programs for mitochondrial diseases, highlighting its upcoming Phase 2 trial for MELAS in Europe and a planned Phase 2a trial for Leigh Syndrome in partnership with a leading US children’s hospital. These developments underscore the company’s commitment to addressing rare mitochondrial disorders using its novel thiol compounds.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1